Clal Biotechnology Industries Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Avi Fischer

Amministratore delegato

₪586.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt

Oct 09

The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet

Apr 18

Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)

Jul 14

Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?

Jan 19

Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings

Mar 25

Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly

Mar 24

Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year

Feb 16

What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?

Jan 12

Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?

Dec 07

AMMINISTRATORE DELEGATO

Avi Fischer (68 yo)

less than a year

Mandato

₪586,000

Compensazione

Dr. Avraham Matityahu Fischer, also known as Avi, M.D., is Co-Managing Partner of Fischer Behar Chen Well Orion & Co. Dr. Fischer is Deputy CEO, Executive VP and Deputy Chairman of Idb Development Corporat...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Avraham Fischer	Chairman & CEO	less than a year	₪586.00k	Nessun dato
Liat Nissan	Chief Financial Officer	2.1yrs	₪975.00k	Nessun dato
Iris Sadeh	Accountant	2.8yrs	Nessun dato	Nessun dato
Shiran Manor	General Counsel & Corporate Secretary	no data	Nessun dato	Nessun dato
Etty Kliger	Vice President of Research & Development - MediWound	no data	₪1.10m	Nessun dato
Lior Rosenberg	Vice President of Medical Technologies - MediWound	no data	₪1.21m	Nessun dato
Arnon Aharon	Medical Director	2.8yrs	Nessun dato	Nessun dato

2.5yrs

Durata media

61.5yo

Età media

Gestione esperta: Il team dirigenziale di CBI è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Avraham Fischer	Chairman & CEO	21.5yrs	₪586.00k	Nessun dato
Yuval Yanai	External Independent Director	8.9yrs	Nessun dato	Nessun dato
Gonen Bieber	Director	less than a year	Nessun dato	Nessun dato
Gad Keren	Independent External Director	4.8yrs	Nessun dato	Nessun dato
Gabriel Barabash	Director	21.7yrs	Nessun dato	Nessun dato
Nufar Malovani	Director	7yrs	Nessun dato	Nessun dato
Tomer Babai	Director	6.9yrs	Nessun dato	Nessun dato

7.0yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CBI sono considerati esperti (durata media dell'incarico 7 anni).

Clal Biotechnology Industries Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt

New major risk - Financial position

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Share price stability

The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet

Third quarter 2022 earnings released: ₪0.015 loss per share (vs ₪0.12 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: ₪0.22 loss per share (vs ₪0.22 loss in 2Q 2021)

Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings

Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS ₪0.68 (vs ₪0.96 loss in FY 2019)

ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

New 90-day low: ₪1.75

Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year

New 90-day high: ₪2.24

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day high: ₪2.23

What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?

Novartis AG (SWX:NOVN) reached a definitive agreement to acquire Cadent Therapeutics, Inc. from a group of sellers for approximately $770 million.

ChemomAb Ltd. entered into a definitive merger agreement to acquire Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?

New 90-day low: ₪1.58

New 90-day high: ₪1.87

New 90-day high - ₪1.76

BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Neon Therapeutics, Inc. (NasdaqGS:NTGN) from Third Rock Ventures, LLC and others.

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media